Clinical trials: OHT - Ocular Hypertension
Glaucoma
Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930
This study is a randomized, open-label, 2-period, parallel group, multiple-dose phase 1 study to evaluate drug-drug Interaction, safety and tolerability in case of the co-administration of D565 and D930, in healthy male subjects
- Trial name
- NCT05207761
- Testing
- D565, D930
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Glaucoma, Retinal Disease
Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100
This study is a prospective comparative study to gather pilot agreement and precision data in normal subjects, subjects with glaucoma, and subjects with retinal disease.
- Conditions
- Glaucoma, Retinal Disease, Healthy
- Trial name
- OCT (NCT03505567)
- Testing
- KOWA OCT Bi-µ, Optovue iVue 100
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Open-angle Glaucoma, Ocular Hypertension
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients
The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00069706
- Testing
- AL-12182 0.003% Ophthalmic Solution, AL-12182 Ophthalmic Solution Vehicle, Latanoprost 0.005% Ophthalmic Solution
- Volunteers
- 118 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of AL-39256 in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00761709
- Testing
- AL-39256 Ophthalmic Suspension, 1%, Latanoprost Ophthalmic Solution, 0.005%, Vehicle
- Volunteers
- 104 people
- Sponsor
- Alcon Research
Ocular Hypertension
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
- Trial name
- NCT00332436
- Testing
- brimonidine/timolol fixed combination
- Where
- United States
- Volunteers
- 586 people
- Sponsor
- Allergan
Open Angle Glaucoma and Ocular Hypertension
A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert
To evaluate the long term safety of repeat dose OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04061044
- Testing
- Ophthalmic Insert
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ocular Therapeutix, Inc.
Primary Open Angle Glaucoma
Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant
To assess the safety and performance of the MIDI Arrow in patients suffering from glaucoma that is inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 40 mm Hg
- Trial name
- NCT01563237
- Testing
- MIDI Arrow
- Where
- France
- Volunteers
- 69 people
- Sponsor
- InnFocus Inc.
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma
Comparing Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery
This clinical trial compares two implantable devices intended to lower the pressure inside the eye of glaucoma patients. One of the two devices will be implanted immediately following cataract surgery and the placement of a…
- Conditions
- Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Pigmentary Dispersion Glaucoma
- Trial name
- NCT02024464
- Testing
- Hydrus Microstent, iStent Trabecular Micro Bypass, Cataract removal and intraocular lens (IOL) implantation
- Volunteers
- 306 people
- Sponsor
- Ivantis, Inc.
Open-angle Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of the study is to evaluate the safety and effectiveness of an investigational therapy for treating patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00293787
- Testing
- Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution, Timolol Vehicle, Latanoprost 0.005% Ophthalmic Solution (XALATAN)
- Volunteers
- 156 people
- Sponsor
- Alcon Research
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost.
- Trial name
- NCT01789736
- Testing
- PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004%
- Where
- 21 sites in United States
- Volunteers
- 234 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Glaucoma Treatment by Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU)
The purpose of this study is to evaluate the effectiveness and the safety of the cyclocoagulation using High Intensity Focused Ulatrsound with the EYEOP1 device in glaucoma patients
- Trial name
- NCT01592955
- Testing
- EYEOP1
- Where
- 7 sites in Israel, Italy and 2 more
- Volunteers
- 84 people
- Sponsor
- EyeTechCare
Glaucoma, Open-Angle, Ocular Hypertension
An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular…
- Trial name
- NCT01735214
- Testing
- Prostaglandin Analogue -Containing IOP-Lowering Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 358 people
- Sponsor
- Allergan
Glaucoma, Open-Angle
H-1337 Ophthalmic Solution Phase 1/2
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with…
- Trial name
- NCT03452033
- Testing
- H-1337 [1], H-1337 [2], H-1337 [3]
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Allysta Pharmaceutical
Glaucoma Treatment Using Focused Ultrasound
UCP Glaucoma Treatment for Primary Glaucoma in China
To collect safety and efficacy data on Ultrasound Cycle Plasty treatment (UCP) in primary glaucoma asian patients.
- Trial name
- NCT04145830
- Testing
- Ultrasound Cyclo Plasty (UCP)
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- EyeTechCare
Raised Intraocular Pressure
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
The purpose of this study is to evaluate the efficacy of systemically administered AZD4017, compared with placebo, over a 28-day period in patients with raised intra-ocular pressure (IOP).
- Trial name
- NCT01173471
- Testing
- AZD4017
- Where
- 11 sites in United States, Sweden and 1 more
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Glaucoma, Open-Angle, Ocular Hypertension
Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension
A study to evaluate the long-term safety of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) in Chinese patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blocker or…
- Trial name
- NCT02571712
- Testing
- bimatoprost 0.03% plus timolol 0.5%
- Where
- 15 sites in China
- Volunteers
- 750 people
- Sponsor
- Allergan
Glaucoma
Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®
Therapeutic indication: Ocular hypotensive Use: Primary open-angle glaucoma and ocular hypertension. Objectives: To evaluate the safety and tolerability of the preservative-free formulation PRO-122 manufactured by Sophia…
- Trial name
- PRO-122/I (NCT03966365)
- Testing
- PRO-122, Krytantek Ofteno®
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Glaucoma
Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery
The objective of this prospective randomised study is to compare the efficacy and safety of ologen CM (Collagen matrix) and Mitomycin-C (MMC) as adjuncts to filtration surgery in uncontrolled treated glaucoma cases, the efficacy…
- Trial name
- MCToCM (NCT01440751)
- Testing
- Use of ologen Collagen Matrix in trabeculectomy (ologen), Use of Mitomycin-C (MMC) in trabeculectomy
- Where
- 8 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aeon Astron Europe B.V.
Glaucoma, Open-Angle
Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma (SAFARI 2)
The purpose of this study is to evaluate the safety and effectiveness of implanting 2 novel interposition supraciliary implant as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle…
- Trial name
- SAFARI 2 (NCT04770324)
- Testing
- Interposition supraciliary implant
- Where
- Armenia
- Volunteers
- 22 people
- Sponsor
- Ciliatech